These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36803449)

  • 1. A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5.
    Duan M; Duan H; An Y; Zheng T; Wan S; Wang H; Zhao X; Dai L; Xu K; Gao GF
    Emerg Microbes Infect; 2023 Dec; 12(1):e2179357. PubMed ID: 36803449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
    Xu K; Gao P; Liu S; Lu S; Lei W; Zheng T; Liu X; Xie Y; Zhao Z; Guo S; Tang C; Yang Y; Yu W; Wang J; Zhou Y; Huang Q; Liu C; An Y; Zhang R; Han Y; Duan M; Wang S; Yang C; Wu C; Liu X; She G; Liu Y; Zhao X; Xu K; Qi J; Wu G; Peng X; Dai L; Wang P; Gao GF
    Cell; 2022 Jun; 185(13):2265-2278.e14. PubMed ID: 35568034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW
    PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    Jia T; Wang F; Chen Y; Liao G; Xu Q; Chen J; Wu J; Li N; Wang L; Yuan L; Wang D; Xie Q; Luo C; Luo H; Wang Y; Chen Y; Shu Y
    J Infect; 2024 Dec; 89(6):106362. PubMed ID: 39608577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study.
    Mi H; Chen Q; Lin H; He T; Zhang R; Ren S; Liu L; Wang J; Huang H; Wang M; Guo Z; Su C
    EClinicalMedicine; 2024 Jan; 67():102374. PubMed ID: 38169940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R;
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.
    Hurst JR; Naghibosadat M; Budowski P; Liu J; Samaan P; Budiman F; Kurtesi A; Qi F; Menon H; Krishnan R; Abioye J; Gingras AC; Ostrowski M; Orozco NM; Kozak RA
    PLoS One; 2024; 19(12):e0314061. PubMed ID: 39625929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants.
    Shrestha LB; Tungatt K; Aggarwal A; Stubis A; Fewings NL; Fichter C; Akerman A; Rodrigo C; Tedla N; Lee S; Lloyd AR; Brilot F; Britton WJ; Kelleher A; Caterson ID; Douglas MW; Rockett R; Tangye SG; Triccas JA; Turville SG; Sandgren KJ; Bull RA; Cunningham AL;
    EBioMedicine; 2024 Dec; 110():105461. PubMed ID: 39612651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.
    Rodriguez-Aponte SA; Dalvie NC; Wong TY; Johnston RS; Naranjo CA; Bajoria S; Kumru OS; Kaur K; Russ BP; Lee KS; Cyphert HA; Barbier M; Rao HD; Rajurkar MP; Lothe RR; Shaligram US; Batwal S; Chandrasekaran R; Nagar G; Kleanthous H; Biswas S; Bevere JR; Joshi SB; Volkin DB; Damron FH; Love JC
    Vaccine; 2023 Jan; 41(5):1108-1118. PubMed ID: 36610932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™.
    Xu S; Duan H; An Y; Jin X; Duan M; Dubois PM; Huang Y; Xu K; Du H; Kleanthous H; Dai L; Gao GF
    Vaccine; 2023 Apr; 41(17):2793-2803. PubMed ID: 36967286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
    Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G
    Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants.
    Mittal N; Kumar S; Rajmani RS; Singh R; Lemoine C; Jakob V; Bj S; Jagannath N; Bhat M; Chakraborty D; Pandey S; Jory A; Sa SS; Kleanthous H; Dubois P; Ringe RP; Varadarajan R
    NPJ Vaccines; 2023 Oct; 8(1):161. PubMed ID: 37880298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.